Technical Resources International Inc.

Pharmacy Market

businesswire | August 25, 2023

Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for CyclASol (ciclosporin ophthalmic solution) for regulatory review. CyclASol is an investigational new drug treatment for dry eye disease in patients not responding to tear substitutes. The Committee for Medicinal Products for Human Use (CHMP) of the EMA will start its review of th...

Business Insights

TherapeuticsMD, Inc | June 01, 2022

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners, a private equity firm dedicated to making investments in rapidly growing healthcare companies. Under the terms of the transaction, which has been unanimously approved by TXMD’s board of directors, EW Healthcare Partners will commence a tender offer to acquire all outstanding sh...

Pharmacy Market

FemTec Health | February 19, 2022

FemTec Health, the leading health and beauty sciences company, announced an exclusive partnership with online pharmacy company GeniusRx that will provide Awesome Woman members access to on-demand, door-to-door medication delivery. Launching later this month, Awesome Woman is FemTec Health's consumer brand that will provide personalized health and wellness services along with products that are meaningful and effective to women at all life stages. Areas of focus include menopaus...

VIEWS AND ANALYSIS, PHARMACY MARKET

prnewswire | May 08, 2023

Telix Pharmaceuticals Limited announces that it has entered into an agreement with Bayer AG to supply Illuccix® kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk bi...